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Abstract
Background: Guillain-Barré syndrome is an acquired polyradiculo-neuropathy, often preceded by an antecedent
event. It is a monophasic disease but a recurrence rate of 1–6 % is documented in a subset group of patients. Patients
with Guillain-Barré syndrome show cerebrospinal fluid albuminocytologic dissociation. Normal cerebrospinal fluid
protein levels during both initial and recurrent episodes of Guillain-Barré syndrome is a rare occurrence and has not
been described earlier in the literature.
Case presentation: Twenty-five-year-old Sri Lankan female with past history of complete recovery following an acute
inflammatory demyelinating polyneuropathy (AIDP) variant of Guillain-Barré syndrome 12 years back presented with
acute, ascending symmetrical flaccid quadriparasis extending to bulbar muscles, bilateral VII cranial nerves and
respiratory compromise needing mechanical ventilation. Nerve conduction study revealed AIDP variant of
Guillain-Barré syndrome. Cerebrospinal fluid analysis done after 2 weeks were normal during both episodes
without albuminocytologic dissociation. She was treated with intravenous immunoglobulin resulting in a remarkable
recovery. Both episodes had a complete clinical recovery in three and four months’ time respectively, rather a faster
recovery than usually expected.
Conclusion: Recurrence of Guillain-Barré syndrome can occur in a subset of patients with Guillain-Barré syndrome
even after many years of asymptomatic period. Normal cerebrospinal fluid profile does not exclude Guillain-Barré
syndrome and may occur in subsequent recurrences of Guillain-Barré syndrome arising the need for further
studies to identify the pathophysiology and the possibility of a different subtype of Guillain-Barré syndrome.
Keywords: Guillain-Barré syndrome, Albuminocytologic dissociation, Acute inflammatory demyelinating polyneuropathy,
Cerebrospinal fluid, Case report
Abbreviations: AIDP, Acute inflammatory demyelinating polyneuropathy; CIDP, Chronic inflammatory demyelinating
polyneuropathy; CSF, Cerebrospinal fluid; GBS, Guillain-Barré syndrome; GBS-TRF, Guillain-Barré syndrome with treatment
related fluctuations; RGBS, Recurrent Guillain-Barré syndrome
Background
Guillain-Barré syndrome (GBS) is an acquired heteroge-
neous group of disorders due to an immune-mediated
inflammation and demyelination of the peripheral nervous
system, following an antecedent illness in two thirds of
the patients, commonly an infection [1–3]. It is a medical
emergency which usually presents with acute onset, rap-
idly progressive symmetrical ascending flaccid paralysis
of the limbs with accompanying absent or diminished
deep tendon reflexes. It is often associated with sensory
symptoms, cranial nerve involvement, less commonly
autonomic dysfunction and respiratory compromise.
GBS is a monophasic illness. Although rare, recurrence
has been described following an asymptomatic period of
few months to years (4 months – 10 years) in 1–6 % of
patients [3–6]. Recurrent GBS (RGBS) is characterized
by 2 or more attacks of acute inflammatory demyelinat-
ing neuropathy with an onset to peak time of 4 weeks
or less, and having complete or near complete recovery
[3, 5]. It is suggested by Kuitwaard et al. that there is a* Correspondence: sonaligunatilake@gmail.com
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subset of patients with GBS who are susceptible for
recurrence, characterized by younger age, milder course
of disease and having Miller-Fisher variant of GBS [3].
Literature revealed that the patients with recurrence
had similar but more severe symptoms and signs in
subsequent episodes while having similar or different
antecedent event [3, 6]. It is important to distinguish
recurrent GBS from GBS with treatment related fluctu-
ations (GBS-TRF) and chronic inflammatory demyelin-
ating polyradiculo-neuropathy (CIDP) as the treatment
regimens are different. Cerebrospinal fluid (CSF) shows
albuminocytologic dissociation in 82–90 % of the pa-
tients with GBS after 10–14 days from onset of the
illness [7]. Electrophysiological studies and CSF analysis
are taken to aid clinical diagnosis of GBS but normal CSF
profile can be found in 10 % of GBS patients throughout
the disease [8]. Therefore normal values cannot rule out
GBS. Grand’maison et al. reported 12 cases of recurrent
GBS (total of 32 episodes), where it was observed that all
patients who were in the symptomatic phase of GBS and
after 1 week of onset of disease showed CSF albuminocy-
tologic dissociation. They observed normal CSF protein
levels which was tested at the onset of disease (within 1
week) in two patients but had not identified a variant of
RGBS with normal CSF protein levels during the symp-
tomatic episodes, tested atleast 1 week after the onset
of symptoms.
We present a rare case of RGBS presenting after 12
years, adding to the limited number of cases with a
long asymptomatic interval. Such reported cases from
South-Asia are rare. Apart from the young age at initial
episode, she did not have other risk factors for recur-
rence and had a rare findings of normal CSF protein
concentrations on both presentations. Extensive litera-
ture survey including published case reports and case
series did not reveal a similar case report of RGBS or
occurrence with normal CSF protein concentrations
during both initial and recurrent presentations of GBS.
Case presentation
A 25-year-old Sri Lankan female presented with weakness
of all four limbs in January 2014. She had a similar illness
12 years back.
First episode
In 2002, at the age of 13 years, patient had noticed tin-
gling sensation of distal upper and lower limbs followed
by weakness of lower limbs, involving both distal and
proximal muscle groups. Weakness was progressive and
ascending, involving both upper limbs and neck muscles
by day 6 of the illness. There was no dysphagia, dysphonia,
respiratory difficulty or bladder/bowel involvement. There
was no significant medical history suggestive of preceding
infection, toxin ingestion or similar disease in the past. On
examination, there was flaccid quadriparesis (muscle
power grade - 3/5) with areflexia in all 4 limbs. There
were no cranial nerve palsies or features suggestive of
autonomic involvement. Sensory system examination
was normal. Full blood count, blood picture, serum
electrolytes, blood urea and liver enzymes profile were
normal. Her erythrocyte sedimentation rate was 13mm
during 1st hour. Nerve conduction studies performed
on day 4 of the illness showed focal segmental demyelinat-
ing type sensory and motor neuropathy with conduction
blocks (Table 1), suggestive of acute inflammatory demye-
linating polyneuropathy (AIDP). EMG studies were not
performed during this episode. CSF analysis on day 14 of
the illness revealed normal results with proteins – 30 g/dl
(normal 15–40 g/dl), white cells 2 with 100 % lymphocytes
and normal CSF glucose levels compared to plasma
values. She was treated with intravenous immunoglobulin
for 5 consecutive days in addition to physiotherapy and
discharged on day 18. She made a complete recovery in
3 months based on normal tone, power and deep tendon
reflexes on neurological examination. Follow-up NCS was
not performed after clinical recovery.
Second episode
In 2014, patient readmitted with numbness and pro-
gressive ascending weakness of all four limbs for 3 days
duration and had developed poor cough response, dys-
phagia and difficulty in breathing during the following
2 days. This episode was preceded by an upper respiratory
tract infection two weeks back. There was no similar ill-
ness noted in any of her family members. On examination,
flaccid quadriparesis with generalized areflexia was noted
with a muscle power of 1/5 in lower limbs, 2/5 in upper
limbs and 2/5 in neck muscles. Weakness progressed to
involve bilateral seventh cranial nerves and bulbar muscle
without ophthalmoplegia. Rest of the neurological exam-
ination including sensory system and other organ system
examination were normal except for a resting tachycardia
of 130 beats/min without any significant blood pressure
fluctuations. Respiratory rate was 30 cycles/min with oxy-
gen saturation of 92 % on air. Nerve conduction studies
done on day 10 of the illness revealed focal segmental
demyelinating type sensory and motor neuropathy with
prolonged distal motor latency, delayed F-wave and
conduction blocks, concluding as AIDP variant of GBS
(Table 1). Electromyogram done on day 10 of the illness
did not show any evidence of denervation but noted
fibrillation potentials of positive sharp waves. CSF analysis
on day 10 and a repeat study on day 24 showed normal
results without cyto-protein dissociation or pleocytosis
(Table 2) Full blood count, blood picture, serum electro-
lytes, erythrocyte sedimentation rate, blood urea and liver
enzymes profile were normal. Serology for Mycoplasma,
Campylobacter jejuni, cytomegalovirus, Epstein-Barr virus,
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hepatitis B & C and retroviral studies were negative.
Autoimmune panel including anti-nuclear factor was
normal. Due to the rapid progressive nature of weak-
ness and respiratory distress, patient was mechanically
ventilated for 12 days. Diagnosis of GBS was made and
intravenous immunoglobulin 0.4 g/kg/day was adminis-
tered for 5 days. In addition, she received physiotherapy
to support her recover in motor function of limbs and
speech therapy following extubation. She made a good
clinical recovery assessed subjectively as well as object-
ively and was discharged home on day 28 with a muscle
power of 4/5 and deep tendon reflexes of +1.
On follow-up, patient had normal neurological exam-
ination findings and subsequent nerve conduction study
after 4 months revealed normal results (Table 1).
Conclusions
GBS is an acute, immune mediated inflammatory
polyradiculo-neuropathy involving the peripheral ner-
vous system. Onset is preceded by an antecedent event
in two thirds of the patients, usually an upper respira-
tory tract infection or a diarrheal illness [1–3], where
Table 2 Laboratory findings of Cerebrospinal fluid during the
initial presentation in 2002 and recurrence of Guillain-Barré
syndrome in 2014
Cerebrospinal fluid profile 2002
episode:







CSF Glucose (mg/dL) 86 78 80
Proteins (g/dL)
(normal: 15 – 40 g/dL)
30 20 26
White blood cells/HPF
(normal: 0 – 5 cells/HPF)
2 4 2
Neutrophils % - - -
Lymphocytes % 100 100 100
Red blood cells/HPF 5 - 10
Random blood glucose tested
at the time of lumba
puncture (mg/dL)
102 110 94
CSF study was performed twice during the episode of recurrence (2014) to
clarify the persistence of normal CSF findings during the course of the illness
Table 1 Nerve conduction study during the initial presentation in 2002 (1st episode) and recurrence (2nd episode) of Guillain-Barre
syndrome in 2014











Median (Right/left) 1st 6.7/6.2 40/45 7.5/11 33/35 Yes
2nd 9.1/8.9 38/40 5.6/ 6 38/40 Yes
Recovery (4 months after 2nd Episode) 4.4/4.5 51 6.0 29 No
Normal Referrence Value <4.4 >49 >4.2 <31
Ulnar (Right/left) 1st 4.6/5.0 42/44 6.0/ 6.2 27/32 Yes
2nd 8.9/9.4 37/41 8.2/ 1.5 36/29 Yes
Normal Referrence Value <3.5 >49 >5.6 <31
Peroneal @ EDB (Right/left) 1st 11.5/13 38/45 2.5/ 2.4 43/49 NP
2nd Absent Absent 1.6/2.0 Absent Yes
Recovery (4 months after 2nd Episode) 5.5 50 2.5 33 No
Normal Referrence Value <5.7 >50 >2.2
Tibial (Right/left) 1st 18.8/18.9 3.0/3.2 52/49 NP
2nd NP NP NP NP NP
Normal Referrence Value >2.8
Sensory
Radial (Right/left) 1st 2.8/ 3.1 38/37 24/23 - -
2nd 2.9/ 3.0 28/33 18/20
Normal Referrence Value <2.6 >43 >20
Sural (Right/left) 1st 2.5/3.0 41/40 34/28
2nd 2.6/2.5 46/48 25/27 - -
Normal Referrence Value <2.6 >52 >24
NP not performed
EDB Extensor digitorum brevis
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the causative agent is assumed to trigger an immune re-
sponse against the gangliosides and glycolipids distributed
along the myelin sheaths and peripheral nervous system.
This results in marked inflammation of the peripheral
nerves, resulting in demyelination and defective impulse
propagation. It is a heterogeneous group of disorders
which involves motor, sensory and autonomic nervous
systems to varying degrees depending on the sub type;
(1) Acute inflammatory demyelinating polyneuropathy,
(2) Acute motor axonal neuropathy, (3) Acute motor
sensory axonal neuropathy, (4) Miller Fisher syndrome,
(5) Acute pan-autonomic neuropathy and (6) Pure sen-
sory GBS.
GBS is a monophasic illness, with an annual incidence
rate of 1.2–3 per 100 000 population [9]. Yet, recurrence
of GBS is observed in 1–6 % of patients, where it is
defined as 2 or more attacks of acute inflammatory de-
myelinating neuropathy with an onset to peak time of 4
weeks or less having complete or near complete recov-
ery [3–6]. The time lag between two episodes of GBS
was 4 months to 10 years in a study done by Das et al.
and a mean of 7 years with a range from 2 months to
37 years was described by Kuitwaard et al. [3, 5]. Patients
tend to get similar clinical presentations and shorter inter-
vals in between subsequent episodes of GBS [3]. Results of
the study by Kuitwaard also found that RGBS patients
were younger, with milder disease and had Miller-Fisher
variant of GBS at the initial episode. Patients with above
characteristics on initial presentation of GBS are more
prone for recurrences [3]. They also identified that there
are similar presentations but more severe clinical deficit
and residual effects with each recurrence [3, 6]. Yet, there
is limited literature addressing why only a certain subset
of patients with GBS get recurrences of the disease. The
indexed case, although young at presentation, patient had
a more alarming disease initially with poor neck muscle
power and limb power and did not have Miller-Fisher
variant. This shows a deviation from the classically
identified features favoring a recurrence of GBS. The
time gap between the episodes was 12 years. During the
episode of recurrence, she had rapid development of
more severe disabling illness involving cranial nerves
and respiratory compromise needing mechanical venti-
lation. Both episodes had AIDP variant of GBS with
similar initial presentations.
The RGBS patients with similar presentations during
the subsequent episodes had different antecedent infec-
tions and this may point towards immunogenic and host
factors as major determinants of the disease [3, 5, 6].
Yet, exact mechanism by which similar clinical manifes-
tations occur during recurrence is not established. Our
patient also had an upper respiratory tract infection pre-
ceding the recurrence of GBS but did not have an event
during the initial episode.
It is important to distinguish RGBS from two clinical en-
tities; (1) GBS with treatment related fluctuations (GBS-
TRF), (2) Chronic inflammatory demyelinating polyneurop-
athy (CIDP). GBS-TRF which occurs in 6–16 % of patients
with GBS is defined as significant deterioration within
2 months after disease onset following post treatment
improvement or stabilization [3]. Repeating immuno-
globulin or plasmaparesis in such patients will improve
the outcome [10]. Since our patient had a long asymp-
tomatic period, GBS-TRF is less likely but CIDP comes
as a differential diagnosis. CIDP is suspected when pro-
gression of weakness lasts more than 8 weeks followed
by a chronic course but it can be of steadily progressive,
relapsing remitting or monophasic. The treatment differs
as CIDP can be treated with either immunoglobulin or
immunosuppressive therapy with a subsequent mainten-
ance immunosuppressive drug treatment whereas GBS
and GBS-TRF do not show a response to immunosup-
pressant therapy but has good response to immunoglobu-
lin or plasmaparesis. GBS is a more likely diagnosis in our
patient as there was a rapid onset of symptoms, subse-
quent complete or near complete recovery, high incidence
of an antecedent illness, normal CSF protein levels at the
onset of a recurrence.
Diagnosis of GBS is mainly clinical and supported by
evidence from electrophysiological studies and CSF ana-
lysis. Characteristically CSF has high protein levels with
normal cell counts and sugar levels. Nerve roots that exit
from the spinal cord traverse through CSF and when
nerve roots are inflamed in GBS, proteins leak in to the
CSF. Since the inflammation is confined to the nerve
roots, significant numbers of inflammatory cells are not
seen. Although normal CSF findings are seen during the
first week of disease, albuminocytologic dissociation is
seen in 82–90 % of the patients with GBS by the end of
second week of the illness [7]. Grand’maison et al. had
also observed normal CSF proteins at the onset of recur-
rent GBS episodes but also noted that it was elevated
when measured after 1 week and when the patient is
symptomatic [4]. 10 % of patients with typical GBS may
have normal CSF findings though out the course of illness
[7, 8, 11] but the pathophysiological mechanism leading to
normal values is not well understood. Medical literature
on above area is not extensive. The index case also had
normal levels of CSF total proteins (performed after 2
weeks of onset of illness) during both episodes of GBS,
which is uncommon and not described in previously re-
ported cases of RGBS.
Study done by Gonzalez-Quevedo et al. revealed raised
CSF total proteins correlated with the degree of inflam-
mation at the nerve roots and higher level of CSF pro-
teins were related to clinical severity [12]. Corston et al.
studied amino acids in CSF of GBS patients quantita-
tively as well as qualitatively. Of the 12 patients studied,
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4 had normal CSF protein levels (<40 g/dL) and in 3 of
them repeat CSF analysis confirmed normal CSF protein
levels. Analysis revealed that 12 amino acids (Eg - ornithine,
lysine, arginine, glycine, alanine plus citrulline, leucine,
tyrosine and phenylalanine) were raised in patients with
high CSF proteins while 6 of the amino acids (alanine
plus citrulline, 2 amino-butyric acid, leucin, ornithine
and lycine) were raised above normal reference range
in patients who had normal CSF total proteins [13].
Three amino acids (phosphoethanolamine, serine and
glutamic acid) in the CSF of GBS patients showed reduced
concentrations. This study highlights the fact that even
when the total protein content in CSF is normal, patients
with GBS have alteration of specific amino acids in CSF.
Our patient had a severe disease with respiratory com-
promise during the recurrence but in contrast to the study
by Gonzalez-Quevedo et al. she had normal CSF protein
levels. Due to the unavailability of the laboratory facilities,
we could not perform the CSF amino acid analysis in
our patient.
Index patient had a recurrence of GBS after a long
asymptomatic period of 12 years as supported by acute
onset, rapid progression, disability peaked within 2 weeks
followed by complete subsequent recovery following treat-
ment, presence of antecedent infection and supportive
electrophysiological evidence. She also had more severe
disease during the recurrence. CSF findings were not
characteristic and were normal during both episodes
occurring 12 years apart, which is a rare finding and
not described earlier in patients with RGBS. Mechanism
behind normal level of CSF proteins during recurrent
episodes remains unclear.
Recurrence of GBS is rare but can occur after many
years of asymptomatic period and is associated with more
severe clinical manifestations. In such a presentation, it is
important to distinguish GBS from CIDP as the treatment
modalities are different. Normal CSF total protein levels
tested after 1 week after the onset of disease can occur in
initial and recurrent episodes of GBS, where the mechan-
ism is not fully understood. Research on recurrent GBS is
needed to evaluate the higher probability of certain sub-
group of patients with GBS for recurrences, to identify the
occurrence and pathophysiology of normal CSF profile
and the possibility of a different subtype in recurrent
GBS patients.
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